Irm LLC

The General Hospital Corporation

Other

The Scripps Research Institute

Novartis Ag

Xu Wu

Qiang Ding

Yahua Liu

Jianwei Che

Barun Okram

Qihui Jin

S Frank Yan

Nathanael Schiander Gray

Sheng Ding

Shifeng Pan

Yongqin Wan

Tetsuo Uno

Hong Liu

Pierre-Yves Michellys

Xiaohui He

Sunil Kumar Panigrahi

Wenqi Gao

Markus Warmuth

Kunyong Yang

Yunho Jin

Jiqing Jiang

Xuefeng Zhu

Dai Cheng

Dong Han

Chandrasekhar Abbineni

Xueshi Hao

Christine Dierks

Yang Sun

Gopala Krishna Jarugumilli

Krishna Chaitanya Talluri

Pranab Maiti

The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcription factor including, e.g., cancer and other diseases.

Small molecule inhibitors of TEAD transcription factors

TEAD transcription factor autopalmitoylation inhibitors

Provided herein are a novel class of compounds of Formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.

Compounds and compositions as Syk kinase inhibitors

The invention provides a novel class of 2,7-naphthyridin derivatives; pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC-GR-1R, Alk, c-FMS, or combinations thereof.

Compounds and compositions as kinase inhibitors

The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I. 

Biphenylcarboxamide derivatives as hedgehod pathway modulators

The invention provides a class of compounds of Formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC, IGR-IR, AIk, c-FMS, or combinations thereof. 

Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors

The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.

Compounds and compositions as hedgehog pathway modulators

The present invention provides compositions and methods for differentiating and transdifferentiating mammalian cells into cells of an osteoblast lineage, using compounds of the following formula: wherein Ris a functional group including, for example, Calkyl, Ccycloalkyl, hydroxyl-Calkyl, aryl-Calkyl, substituted with 0-2 Rgroups, and heterocyclo-Calkyl, optionally substituted with Calkyl; Ris hydrogen and Ris a functional group including, for example, halogen, Calkyl, &#x2014;C(O)&#x2014;Calkyl, &#x2014;SO&#x2014;N(RR), halo&#x2014;Calkyl, &#x2014;O-aryl and &#x2014;N(RR), or when Rand Rare on adjacent ring atoms they are optionally taken together to form &#x2014;O&#x2014;(CH)&#x2014;O&#x2014;; and all pharmaceutically acceptable salts and hydrates thereof.

Compositions and methods for inducing osteogenesis

Growing community of inventors

San Diego, CA, United States of America

Xu Wu